Brachiterapia prostatica low-dose rate nel paziente anziano

Translated title of the contribution: Low-dose rate brachytherapy of the prostate in elderly patients

C. Chiumento, A. Fiorentino, R. Caivano, S. Clemente, V. Fusco

Research output: Contribution to journalArticle

Abstract

Purpose. This study evaluated the biochemical diseasefree survival (bDFS) rate, overall survival rate (OS) and toxicity after low-dose rate I125 permanent-implant prostate brachytherapy (LDR-BRT) in elderly patients affected by prostate cancer. Methods and materials. Patients aged ≥65 years with a diagnosis of prostate cancer and treated at our institution were retrospectively evaluated. All patients received LDR-BRT as monotherapy; the prescribed dose was 145 Gy to the prostate. Patients were stratified according to the National Comprehensive Cancer Network (NCCN) recurrence risk groups. Biochemical failure was defined according to the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria. The Radiation Therapy Oncology Group (RTOG) scale was used for toxicity. The bDFS was calculated from implant date to biochemical recurrence. Results. Between June 2003 and December 2008, 80 elderly patients with a median age of 75 (range, 65-86) years were treated with LDR-BRT: 51 low risk (64%), and 29 intermediate risk (36%). Over a median follow-up period of 53 (range, 28-94) months, the global actuarial 5-year bDFS rate was 91.3% and the 5-year OS was 95%. Toxicity was mild: late grade-3 genitourinary toxicity was observed in only four patients (5%) . Conclusions. Our data suggest that LDR-BRT is effective and safe as monotherapy in elderly patients.

Original languageItalian
Pages (from-to)1412-1421
Number of pages10
JournalRadiologia Medica
Volume118
Issue number8
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Brachytherapy
Prostate
Survival Rate
Radiation Oncology
Prostatic Neoplasms
Recurrence
Radiotherapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Brachiterapia prostatica low-dose rate nel paziente anziano. / Chiumento, C.; Fiorentino, A.; Caivano, R.; Clemente, S.; Fusco, V.

In: Radiologia Medica, Vol. 118, No. 8, 12.2013, p. 1412-1421.

Research output: Contribution to journalArticle

Chiumento, C. ; Fiorentino, A. ; Caivano, R. ; Clemente, S. ; Fusco, V. / Brachiterapia prostatica low-dose rate nel paziente anziano. In: Radiologia Medica. 2013 ; Vol. 118, No. 8. pp. 1412-1421.
@article{7b6047017da6486bb9b2cdabf8a0370c,
title = "Brachiterapia prostatica low-dose rate nel paziente anziano",
abstract = "Purpose. This study evaluated the biochemical diseasefree survival (bDFS) rate, overall survival rate (OS) and toxicity after low-dose rate I125 permanent-implant prostate brachytherapy (LDR-BRT) in elderly patients affected by prostate cancer. Methods and materials. Patients aged ≥65 years with a diagnosis of prostate cancer and treated at our institution were retrospectively evaluated. All patients received LDR-BRT as monotherapy; the prescribed dose was 145 Gy to the prostate. Patients were stratified according to the National Comprehensive Cancer Network (NCCN) recurrence risk groups. Biochemical failure was defined according to the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria. The Radiation Therapy Oncology Group (RTOG) scale was used for toxicity. The bDFS was calculated from implant date to biochemical recurrence. Results. Between June 2003 and December 2008, 80 elderly patients with a median age of 75 (range, 65-86) years were treated with LDR-BRT: 51 low risk (64{\%}), and 29 intermediate risk (36{\%}). Over a median follow-up period of 53 (range, 28-94) months, the global actuarial 5-year bDFS rate was 91.3{\%} and the 5-year OS was 95{\%}. Toxicity was mild: late grade-3 genitourinary toxicity was observed in only four patients (5{\%}) . Conclusions. Our data suggest that LDR-BRT is effective and safe as monotherapy in elderly patients.",
keywords = "Brachytherapy, Elderly patients, Outcomes, Prostate cancer",
author = "C. Chiumento and A. Fiorentino and R. Caivano and S. Clemente and V. Fusco",
year = "2013",
month = "12",
doi = "10.1007/s11547-012-0872-0",
language = "Italian",
volume = "118",
pages = "1412--1421",
journal = "Radiologia Medica",
issn = "0033-8362",
publisher = "Springer-Verlag Italia s.r.l.",
number = "8",

}

TY - JOUR

T1 - Brachiterapia prostatica low-dose rate nel paziente anziano

AU - Chiumento, C.

AU - Fiorentino, A.

AU - Caivano, R.

AU - Clemente, S.

AU - Fusco, V.

PY - 2013/12

Y1 - 2013/12

N2 - Purpose. This study evaluated the biochemical diseasefree survival (bDFS) rate, overall survival rate (OS) and toxicity after low-dose rate I125 permanent-implant prostate brachytherapy (LDR-BRT) in elderly patients affected by prostate cancer. Methods and materials. Patients aged ≥65 years with a diagnosis of prostate cancer and treated at our institution were retrospectively evaluated. All patients received LDR-BRT as monotherapy; the prescribed dose was 145 Gy to the prostate. Patients were stratified according to the National Comprehensive Cancer Network (NCCN) recurrence risk groups. Biochemical failure was defined according to the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria. The Radiation Therapy Oncology Group (RTOG) scale was used for toxicity. The bDFS was calculated from implant date to biochemical recurrence. Results. Between June 2003 and December 2008, 80 elderly patients with a median age of 75 (range, 65-86) years were treated with LDR-BRT: 51 low risk (64%), and 29 intermediate risk (36%). Over a median follow-up period of 53 (range, 28-94) months, the global actuarial 5-year bDFS rate was 91.3% and the 5-year OS was 95%. Toxicity was mild: late grade-3 genitourinary toxicity was observed in only four patients (5%) . Conclusions. Our data suggest that LDR-BRT is effective and safe as monotherapy in elderly patients.

AB - Purpose. This study evaluated the biochemical diseasefree survival (bDFS) rate, overall survival rate (OS) and toxicity after low-dose rate I125 permanent-implant prostate brachytherapy (LDR-BRT) in elderly patients affected by prostate cancer. Methods and materials. Patients aged ≥65 years with a diagnosis of prostate cancer and treated at our institution were retrospectively evaluated. All patients received LDR-BRT as monotherapy; the prescribed dose was 145 Gy to the prostate. Patients were stratified according to the National Comprehensive Cancer Network (NCCN) recurrence risk groups. Biochemical failure was defined according to the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria. The Radiation Therapy Oncology Group (RTOG) scale was used for toxicity. The bDFS was calculated from implant date to biochemical recurrence. Results. Between June 2003 and December 2008, 80 elderly patients with a median age of 75 (range, 65-86) years were treated with LDR-BRT: 51 low risk (64%), and 29 intermediate risk (36%). Over a median follow-up period of 53 (range, 28-94) months, the global actuarial 5-year bDFS rate was 91.3% and the 5-year OS was 95%. Toxicity was mild: late grade-3 genitourinary toxicity was observed in only four patients (5%) . Conclusions. Our data suggest that LDR-BRT is effective and safe as monotherapy in elderly patients.

KW - Brachytherapy

KW - Elderly patients

KW - Outcomes

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84892938822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892938822&partnerID=8YFLogxK

U2 - 10.1007/s11547-012-0872-0

DO - 10.1007/s11547-012-0872-0

M3 - Articolo

C2 - 22986692

AN - SCOPUS:84892938822

VL - 118

SP - 1412

EP - 1421

JO - Radiologia Medica

JF - Radiologia Medica

SN - 0033-8362

IS - 8

ER -